154 related articles for article (PubMed ID: 8354335)
1. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
Kleinveld HA; Demacker PN; De Haan AF; Stalenhoef AF
Eur J Clin Invest; 1993 May; 23(5):289-95. PubMed ID: 8354335
[TBL] [Abstract][Full Text] [Related]
2. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
[TBL] [Abstract][Full Text] [Related]
3. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
Tilly-Kiesi M; Tikkanen MJ
J Intern Med; 1991 May; 229(5):427-34. PubMed ID: 2040869
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
5. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Pazzucconi F; Dorigotti F; Gianfranceschi G; Campagnoli G; Sirtori M; Franceschini G; Sirtori CR
Atherosclerosis; 1995 Oct; 117(2):189-98. PubMed ID: 8801864
[TBL] [Abstract][Full Text] [Related]
6. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
[TBL] [Abstract][Full Text] [Related]
7. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
Stalenhoef AF; Lansberg PJ; Kroon AA; Kortmann B; De Haan AF; Stuyt PM; Kastelein JJ
J Intern Med; 1993 Jul; 234(1):77-82. PubMed ID: 8326293
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Richter WO; Jacob BG; Schwandt P
Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies.
Vitols S; Angelin B; Juliusson G
Lipids; 1997 Mar; 32(3):255-62. PubMed ID: 9076662
[TBL] [Abstract][Full Text] [Related]
10. Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin.
Lintott CJ; Scott RS; Sutherland WH; Bremer J
Aust N Z J Med; 1993 Aug; 23(4):381-6. PubMed ID: 8240151
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Sakai M; Kobori S; Matsumura T; Biwa T; Sato Y; Takemura T; Hakamata H; Horiuchi S; Shichiri M
Atherosclerosis; 1997 Aug; 133(1):51-9. PubMed ID: 9258407
[TBL] [Abstract][Full Text] [Related]
12. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Conde K; Pineda G; Newton RS; Fernandez ML
Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
[TBL] [Abstract][Full Text] [Related]
13. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.
Mabuchi H; Haba T; Tatami R; Miyamoto S; Sakai Y; Wakasugi T; Watanabe A; Koizumi J; Takeda R
N Engl J Med; 1981 Aug; 305(9):478-82. PubMed ID: 7254297
[TBL] [Abstract][Full Text] [Related]
14. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Illingworth DR; Bacon S
Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
[TBL] [Abstract][Full Text] [Related]
15. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
Feillet C; Farnier M; Monnier LH; Percheron C; Colette C; Descomps B; Crastes De Paulet A
Atherosclerosis; 1995 Dec; 118(2):251-8. PubMed ID: 8770319
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
Thiery J; Creutzfeldt C; Creutzfeldt W; Walli AK; Seidel D
Klin Wochenschr; 1990 Aug; 68(16):814-22. PubMed ID: 2214604
[TBL] [Abstract][Full Text] [Related]
18. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Erkelens DW
Cardiology; 1990; 77 Suppl 4():33-8. PubMed ID: 2073670
[TBL] [Abstract][Full Text] [Related]
19. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
Thallinger C; Urbauer E; Lackner E; Graselli U; Kostner K; Wolzt M; Joukhadar C
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):551-7. PubMed ID: 16372516
[TBL] [Abstract][Full Text] [Related]
20. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
